2 December 2013 - Janssen Inc. announced today that Health Canada has approved Simponi I.V. (golimumab) for infusion for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate. Simponi I.V. is the first and only fully human anti-tumour necrosis factor (TNF)-alpha infusible therapy approved in Canada to treat moderately to severely active RA.

For more details, go to: http://www.janssen.ca/media